Williams Laura A
Known title: Chief Medical OfficerCIK: 0001869194
Williams Laura A's purchase track record
Williams Laura A has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 3,486 | $13K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,089 | $12K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,430 | $9K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,734 | $7K | 8/21/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 31,000 | $31K | 6/18/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 81,898 | $490K | 6/18/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,157 | $14K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,911 | $12K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,418 | $9K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,503 | $9K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,192 | $42K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 984 | $6K | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 82,695 | $0 | 1/23/2026 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 50,000 | $50K | 1/8/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 50,000 | $349K | 1/8/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,426 | $36K | 11/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 30,000 | $184K | 8/26/2025 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 50,000 | $50K | 8/26/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 50,000 | $306K | 8/26/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,261 | $37K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,421 | $26K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 105,200 | $0 | 2/25/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,941 | $28K | 2/20/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,366 | $35K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,412 | $43K | 8/20/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 100,000 | $275K | 6/5/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 45,000 | $321K | 6/5/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 100,000 | $713K | 6/5/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,794 | $37K | 5/21/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 30,000 | $30K | 5/3/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 39,949 | $334K | 5/3/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,803 | $42K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 118,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,581 | $11K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 25,000 | $100K | 11/15/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,591 | $9K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 25,000 | $84K | 6/27/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,583 | $9K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,187 | $10K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 15 | $29 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 33 | $64 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,193 | $2K | 11/22/2022 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,263 | $1K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 13 | $13 | 8/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.